Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. - Wikidata - wikimedia - TriplyDB

Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes.

Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes.

http://www.wikidata.org/entity/Q46470676

about

Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic Approaches Nitric oxide synthases: regulation and function Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats.Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat Vascular endothelial function and hypertension: insights and directions Depletion of endothelial or smooth muscle cell-specific angiotensin II type 1a receptors does not influence aortic aneurysms or atherosclerosis in LDL receptor deficient mice.Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors.Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials.Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling.Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis.Dahl salt-sensitive rats are protected against vascular defects related to diet-induced obesity Differential effects of dietary sodium intake on blood pressure and atherosclerosis in hypercholesterolemic mice.Augmentation of the renin-angiotensin system by hypercholesterolemia promotes vascular diseases.The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies Aliskiren Inhibits Neointimal Matrix Metalloproteinases in Experimental Atherosclerosis.Managing cardiovascular and renal risk: the potential of direct renin inhibition.Aliskiren improves vascular smooth muscle function in the skin microcirculation of type 2 diabetic patients with normal renal function Direct renin inhibition with aliskiren protects against myocardial ischemia/reperfusion injury by activating nitric oxide synthase signaling in spontaneously hypertensive rats.Induction of microRNA-138 by pro-inflammatory cytokines causes endothelial cell dysfunction.Is there a future for direct renin inhibitors?Unmet needs in managing hypertension: potential role of direct renin inhibition.Aliskiren: beyond blood pressure reduction.New class of agents for treatment of hypertension: focus on direct renin inhibition.Direct renin inhibition: update on clinical investigations with aliskiren.Reducing cardiovascular events and end-organ damage in patients with hypertension: new considerations.Roles of the WHHL rabbit in translational research on hypercholesterolemia and cardiovascular diseases.Nitric oxide: orchestrator of endothelium-dependent responses.Is tetrahydrobiopterin a therapeutic option in diabetic hypertensive patients?Aliskiren as a novel therapeutic agent for hypertension and cardio-renal diseases.Oral renin inhibitors in clinical practice: a perspective review Redox-sensitive mechanisms underlying vascular dysfunction in heart failure.Endothelial cell dysfunction as a novel therapeutic target in atherosclerosis.Aliskiren improves endothelium-dependent relaxation of thoracic aorta by activating PI3K/Akt/eNOS signal pathway in SHR.Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser(1177)/Thr(497) of endothelial nitric oxide synthase in diabetic mice.Effect of aliskiren, telmisartan and torsemide on cardiac dysfunction in l-nitro arginine methyl ester (l-NAME) induced hypertension in rats.Differential effects of aliskiren/amlodipine combination and high-dose amlodipine monotherapy on endothelial function in elderly hypertensive patients.MRI assessment of coronary microvascular endothelial nitric oxide synthase function using myocardial T1 mapping.Aliskiren and Valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice.A Color Segmentation-Based Method to Quantify Atherosclerotic Lesion Compositions with Immunostaining.Diesel exhaust particles impair endothelial progenitor cells, compromise endothelial integrity, reduce neoangiogenesis, and increase atherogenesis in mice.

P2860

Q26785504-BFF61CBF-D2F7-4535-A0C0-809ADFD4F5BA Q28247092-B55CC99A-8D2D-4B0E-85D2-A296501E335F Q30415495-4BADFB9B-A6FD-4F96-B485-45491BE820A4 Q33727755-18CA8712-B885-4360-A167-8AABC211E4DB Q34316160-65ED175E-0C9F-40AE-A703-09617669FE3C Q34511040-8744818B-4CE9-4586-89E5-0C393D524760 Q34608252-A430EB9D-0907-4038-84B7-B49747B09414 Q34905891-9F573F5B-9E8D-439B-B115-152864290350 Q35216447-4A4F0D36-0FEE-46DF-8EC7-7DA4B02B180C Q36025434-C7EA90C6-6627-433E-B154-B7B1320035F8 Q36239236-93866BF5-760A-4900-ABC6-E911B72F01D5 Q36599243-7D6258CC-C7D6-4E48-8856-F7FE888DEA75 Q37086076-B3D576EC-EDBA-4DAC-ACCE-E9494423C4E2 Q37158159-7747B237-4371-4B95-B48B-0E0A5B2F9F7E Q37314525-3890649B-CF36-4532-A7D9-B9D9E0D700E0 Q37510348-5F9024D2-EFA3-4B19-A783-4F810C4DBDAC Q37619165-40EBE5A9-E0B2-42AA-A5E7-F5646A64D769 Q37648622-AB18AC66-0DE2-4FF1-8F5B-A82B0EFDDC26 Q37683440-8E6B9F3C-B945-46B5-AC06-1794297EF472 Q37727965-E8C20708-C1CA-447E-8C40-215451174948 Q37750291-2262FE0C-99B1-49D6-9C97-86E5930B3A95 Q37784830-7AFF472B-CC68-48AC-A4D6-E2257AD51BAA Q37801292-BB043A06-F717-4419-8859-143DF4B6F670 Q37859528-D96F4251-8F6A-42DB-A2C2-062816AF9744 Q37862922-2A585ADC-CBC1-4D27-8CD4-C361D2081D28 Q37871868-F6206299-DB9F-434A-876C-AD454040AC69 Q37927098-442C760E-658A-488B-B9B4-ECB691948711 Q37939136-6C45F8D6-2C88-4BF7-8549-AF1128B85DF9 Q37993917-1F003E35-3E0E-4757-8782-4E67C49E0DEB Q38076124-2D96ABE8-A6AF-48EE-A41D-AB3E0F0FEAD8 Q38383375-22B066D5-683D-4414-9198-2113012F7519 Q38881790-42CD7345-8722-4675-B9C5-8E2270DABA80 Q40067806-2505B103-B755-47A1-9BB8-446B046D75C7 Q41922933-D1BB4BC7-577F-4475-A9C1-FD455BC755FA Q43179386-5E4FBE7F-3F9D-4F45-8F46-7D1078D50533 Q44623946-BDAC84E7-6385-4AC0-B626-79593F15D435 Q45064829-3961A9FB-ED7F-4D8A-9F21-171BC892A0EC Q47350464-9D2A5C81-142B-40FD-A9F3-307E76A40909 Q51004437-A48D85DC-14D9-4D68-8377-3047AFA1C5D9 Q51069248-47409483-AEDC-40DC-BE35-6B134855FE73

P2860

Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes.

http://www.wikidata.org/entity/Q46470676

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Renin inhibitor aliskiren impr ...... ainst atherosclerotic changes.

@en

Renin inhibitor aliskiren impr ...... ainst atherosclerotic changes.

@nl

type

label

Renin inhibitor aliskiren impr ...... ainst atherosclerotic changes.

@en

Renin inhibitor aliskiren impr ...... ainst atherosclerotic changes.

@nl

prefLabel

Renin inhibitor aliskiren impr ...... ainst atherosclerotic changes.

@en

Renin inhibitor aliskiren impr ...... ainst atherosclerotic changes.

@nl

P1433

Q46470676-E708FD67-4AC0-4912-91AF-60AF9A3D0E86

P1476

Q46470676-6576D68E-73AD-4FC6-A621-4A7D2228DE28

P2093

Q46470676-045C3566-31E5-4CB2-9831-3ED12C7BC0C0

Q46470676-0B9C33B7-4744-41AC-BB10-6B1F9226AC61

Q46470676-1D4D5A62-B1D1-404B-8BE1-5A21127A5CDC

Q46470676-5BEDE7FF-56A1-483E-B034-DF5936BEF781

Q46470676-5DE4C0D0-EB04-4E6E-93F9-28DAF597B494

Q46470676-6060807B-1053-420C-B5AB-8DBC5C158995

Q46470676-758FB4DB-A6BA-4489-904A-8E98503AFC07

Q46470676-8F4DA090-6DCC-4FDC-B407-42540C9090EC

Q46470676-965D40E8-6272-46D3-9753-F430025F49DF

Q46470676-A2382875-AC6D-469A-A644-00CBED073BD7

P304

Q46470676-50B133B5-8629-4F79-A985-C6E570DBED09

P31

Q46470676-DADAA3C6-AF65-4A42-B836-A891C4CD7C19

P356

Q46470676-018C5DD6-40BB-469A-8EC1-2748E0FC9729

P407

Q46470676-FB892DFA-DEA8-4058-9271-EE9EDC740935

P433

Q46470676-45502F76-C332-42D5-A266-486822D8AB64

P478

Q46470676-C74C1C7C-206D-4DC2-9530-C96400C8C303

P577

Q46470676-2E94FA2C-F816-4BD7-8F99-755DCF523298

P698

Q46470676-44DAD5A1-D7BC-4D76-BD2B-4BB7FBACA160

P921

Q46470676-0D2F67E2-B2A7-44CC-B637-AE187E3BCE00

P356

HYPERTENSIONAHA.108.111120

P1433

P1476

Renin inhibitor aliskiren impr ...... ainst atherosclerotic changes.

@en

P2093

Akio Kuroi

http://www.w3.org/2001/XMLSchema#string

Hideyuki Ikejima

http://www.w3.org/2001/XMLSchema#string

Hironori Kitabata

http://www.w3.org/2001/XMLSchema#string

Hiroto Tsujioka

http://www.w3.org/2001/XMLSchema#string

Kiyoshi Yoshida

http://www.w3.org/2001/XMLSchema#string

Masami Goto

http://www.w3.org/2001/XMLSchema#string

Seiichi Mochizuki

http://www.w3.org/2001/XMLSchema#string

Shigeho Takarada

http://www.w3.org/2001/XMLSchema#string

Takashi Akasaka

http://www.w3.org/2001/XMLSchema#string

Takashi Tanimoto

http://www.w3.org/2001/XMLSchema#string

P304

563-572

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/HYPERTENSIONAHA.108.111120

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2008-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18645051

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis